Xilio Therapeutics Inc（XLO）财务数据XLOXilio Therapeutics Inc

Evaluating the bottom line, Xilio Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.68%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively XLO converts its operational activities into shareholder value.

In the context of the broader market, XLO competes directly with industry leaders such as TLPH and EDSA. With a market capitalization of $60.34M, it holds a significant position in the sector. When comparing efficiency, XLO's gross margin of N/A stands against TLPH's N/A and EDSA's N/A. Such benchmarking helps identify whether Xilio Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Xilio's financial performance shows a significant net income of $10.36 million for Q4 2025, but it has also reported substantial losses in previous quarters, including a net loss of -$9.5 million in Q1 2026. Revenue growth is promising, with Q2 2026 collaboration revenue at $18.7 million, a 131% increase from the previous year.